SCHEMBL14712877

SCHEMBL14712877

CCN1C(=O)NC(=O)/C(=C\C=C\c2ccc(N(C)C)cc2)C1=O

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 13/20 0.64
MEN1 O00255 7/20 0.64
KMT2A Q03164 7/20 0.64
ALDH1A1 P00352 5/20 0.64
PKM P14618 2/20 0.64
MAPK1 P28482 2/20 0.64
L3MBTL1 Q9Y468 2/20 0.64
NPSR1 Q6W5P4 2/20 0.64
PSMD14 O00487 1/20 0.64
MMP2 P08253 1/20 0.64
THRB P10828 1/20 0.64
PPARG P37231 1/20 0.64
NCOA2 Q15596 1/20 0.64
METAP1 P53582 2/20 0.64
APP P05067 9/20 0.56
SNCA P37840 7/20 0.56
MITF O75030 2/20 0.53
SMN1; SMN2 Q16637 2/20 0.53
KDM4E B2RXH2 2/20 0.51
HPGD P15428 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14713023 0.86 MAPT (0.52) MAPTMEN1KMT2AALDH1A1PKM
SCHEMBL14712900 0.86 MAPT (0.56) MAPTMEN1KMT2AALDH1A1PKM
SCHEMBL14713066 0.85 MEN1 (0.64) MAPTMEN1KMT2AALDH1A1PKM
SCHEMBL14712892 0.84 MAPT (0.72) MAPTMEN1KMT2AALDH1A1PKM
SCHEMBL14712899 0.82 MAPT (0.56) MAPTMEN1KMT2AALDH1A1PKM
SCHEMBL14713028 0.82 MAPT (0.67) MAPTMEN1KMT2AALDH1A1PKM
SCHEMBL14712975 0.82 METAP1 (0.56) MAPTMEN1KMT2AALDH1A1PKM
SCHEMBL16543003 0.78 METAP1 (1.00) MAPTMEN1KMT2AALDH1A1PKM
SCHEMBL14712989 0.78 KMT2A (0.48) MAPTMEN1KMT2AALDH1A1PKM
SCHEMBL29350119 0.78 MAPT (1.00) MAPTMEN1KMT2AALDH1A1PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9994554-B2 Barbiturate and thiobarbiturate compounds for use in cancer therapy NUHOPE LLC (US) 2018-06-12 US disclosed
US-9994554-B2 Barbiturate and thiobarbiturate compounds for use in cancer therapy NUHOPE LLC (US) 2018-06-12 US disclosed
US-20180134691-A1 BARBITURATE AND THIOBARBITURATE COMPOUNDS FOR USE IN CANCER THERAPY NUHOPE, LLC (US) 2018-05-17 US disclosed
US-20180134691-A1 BARBITURATE AND THIOBARBITURATE COMPOUNDS FOR USE IN CANCER THERAPY NUHOPE, LLC (US) 2018-05-17 US disclosed
US-9878998-B2 Barbiturate and thiobarbiturate compounds for use in cancer therapy NUHOPE LLC (US) 2018-01-30 US disclosed
US-9878998-B2 Barbiturate and thiobarbiturate compounds for use in cancer therapy NUHOPE LLC (US) 2018-01-30 US disclosed
US-20150065531-A1 COMPOUNDS FOR USE IN CANCER THERAPY CONNOR, JAMES R. 2015-03-05 US disclosed
US-20150065531-A1 COMPOUNDS FOR USE IN CANCER THERAPY CONNOR, JAMES R. 2015-03-05 US disclosed
WO-2013024447-A1 COMPOUNDS FOR USE IN CANCER THERAPY NUHOPE, LLC (US) 2013-02-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180134691-A1 BARBITURATE AND THIOBARBITURATE COMPOUNDS FOR USE IN CANCER THERAPY MGMT, BCL2, BAX MAPT 2828/4885MEN1 2410/4885KMT2A 2749/4885
US-20150065531-A1 COMPOUNDS FOR USE IN CANCER THERAPY MGMT, BCL2, BAK1 MAPT 3272/4885MEN1 1885/4885KMT2A 3262/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.